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impact of RVI screening on respiratory-related NRM was
assessed.
Method: Consecutive allo-HSCT patients (pts) experiencing
NRM between 1/00 e 1/14 were identiﬁed from a prospec-
tively maintained database. NRM episodes were assessed
pre- and post-RVI screening and an etiology assigned
following medical record review and treating physician
determination. RVI were identiﬁed in symptomatic pts from
nasal/pharyngeal swabs or bronchoalveloar lavage speci-
mens using PCR or immunoﬂuorescence.
Results: 204 allo-HSCT were evaluated, 118 pre- and 86 post-
RVI screening. For the entire cohort: male:female ratio was
1.4:1, median age 52 (17-71) years, median follow up 24.2
(2.4-154) months. Most common pre-HSCT diagnoses were
myeloid malignancies (43%), NHL (22%) ALL (12%). 3 year DFS
and OS was 50.7% and 59.6%. There were no signiﬁcant dif-
ferences between study cohorts. There was a signiﬁcant
difference between pre-RV and post-RV cohorts in condi-
tioning intensity (MA 46% vs 19%, NMA 53% vs 81%, p<0.01),
donor source (MS 71% vs 29%, MUD 0 vs 44%, p<0.01) and
TBI-based conditioning (20% vs 51%, p<0.01) reﬂecting
changes in departmental practice. Most common RVI’s were
rhinovirus (40%), RSV (30%), parainﬂuenza (20%) and coro-
navirus (10%).
Overall NRM was 24.5%.Pre- and post-RVI screening NRM
was 22.9% and 26.7% (p¼0.53). 12/26 (46%) NRM events were
respiratory-related pre-RVI vs 6/24 (25%) post-RVI (RR 0.54,
95%CI 0.24-1.22, p¼0.14). Post-RVI screening, viral pneumo-
nitis was the cause of respiratory death in 2/5 pts (1¼RSV,
1¼rhinovirus).
Conclusion: Respiratory-related deaths represent a signiﬁ-
cant NRM burden post allo-HSCT. RVI screening may impact
on respiratory-related NRM in allo-HSCT.417
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Background: The proteasome inhibitor Bortezomib has been
successfully used to prevent the development of graft-
versus-host disease (GVHD) in recipients of matched unre-
lated donor (MUD) or mismatch related donor (mMRD)
allogeneic HSCT. We sought to evaluate the efﬁcacy of this
agent in our patient population and assess its impact on
neutrophil engraftment when G-CSF support was not
routinely utilized.
Methods: We conducted a retrospective review of patients
(pts) with hematologic malignancies who underwent MUD
allogeneic HSCT at our institution and received GVHD pro-
phylaxis with bortezomib (dose 1.3 mg/m2) administered on
days +1, +4, and +7 after stem cell infusion, in addition to
standard prophylaxis with tacrolimus and methotrexate.
Since our ﬁrst treated patient developed hyper-acute GVHD,standard G-CSF support was omitted and reserved only for
pts with severe sepsis or delayed engraftment.
Results: Twenty-one MUD recipients receiving bortezomib-
based GVHD prophylaxis were transplanted at our institution
between 2012 and 2014. Median age was 51 years (range:
34-62 yrs); male to female ratio 2:1. Indications for trans-
plantation included: AML (11/52.4%), ALL (6/28.6%), MPN (2/
9.5%) CLL (1/4.8%) and NHL(1/4.8%). Graft source was mobi-
lized peripheral blood stem cells for all pts. Seven pts (33.3%)
received a myeloablative conditioning regimen, whereas 14
pts (66.7%) received a reduced-intensity regimen. Median
donor chimerism at days +30 and +100 was 98.5% (range 70-
99%) and 98% (range 81-99%) respectively. Median time for
neutrophil engraftment was 14.38 days +/- 1.86. Cumulative
incidence of grade III-IV aGVHD at day +100 was 14.3%. Non-
relapse mortality (NRM) at day +100 was 9.5% and the
cumulative incidence of relapse was 4.8% at day +180 and
19% at 1 year.
Conclusions: Bortezomib-based GVHD prophylaxis resulted
in acceptable rates of acute GVHD and non-relapsemortality;
our results are encouraging and similar to those available in
the current literature. The use of bortezomib did not result in
delayed engraftment or graft failure (when compared to
historical controls) even when standard growth factor sup-
port was omitted in patients undergoing MUD transplant.418
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Prognosis after allogeneic hematopoietic stem cell trans-
plantation (SCT) in patients with relapsed or refractory he-
matologic malignancies at the time of SCT is poor due to the
increased risk of relapse or TRM. Several intensiﬁed condi-
tioning regimens have been reported, however, long term
outcome after 5 years was not clariﬁed. This study is aimed to
evaluate the long term outcome of SCT with intensiﬁed
conventional myeloablative conditioning regimen.
We retrospectively analyzed a total of 59 adult patients with
advanced hematologic malignancies including refractory
AML(n¼32), CML with blastic crisis (n¼14), refractory ALL
(n¼8) and others (n¼5) who received allogeneic SCT with
intensiﬁed myeloablative conditioning regimen of busulfan
(BU) 8mg/kg + cyclophosphamide 120mg/kg + TBI 10Gy
(n¼20), melphalan (MEL) 180mg/m2 + BU 8mg/kg + TBI 10Gy
(n¼32) or MEL180 mg/m2+ TBI 10Gy (n¼7) from January
1994 to December 2003 in our institution. GVHD prophylaxis
consisted with tacrolimus or cyclosporine and short courses
of methotrexate.
The median follow-up of the surviving patients was 8.3 years
(0.1-18.8). Median age at transplant was 36 (17-54). Fifty-one
patients received BM, 4 received PBSC, 1 received both and 3
received CB; 18 from a matched related donor, 15 from a
matched unrelated donor, 7 from a mismatched related
donor and 19 from a mismatched unrelated donor. Rejection
was observed in only 1 patient. A total of 44.6% and 23.2% of
evaluable patients had grade II-IV and grade III-IV acute
GVHD, respectively and 57.9% of evaluable patients experi-
enced extensive chronic GVHD. Overall survival and disease-
free survival at 5 years was 31.5% and 29.7%, whereas that at
